Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 304, Issue -, Pages 63-71Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2016.09.017
Keywords
Multiple sclerosis; Experimental autoimmune encephalomyelitis; Estrogen; Pregnancy; Neuroprotection
Categories
Funding
- National Multiple Sclerosis Society's Fast Forward Program
- Conrad N. Hilton Foundation [20150232]
- California Community Foundation [BAPP-15-118094]
- Jack H. Skirball Foundation
- Tom Sherak MS Hope Foundation
- UCLA Laboratories of Neuroendocrinology Training Grant [5T32HD007228]
Ask authors/readers for more resources
Protective effects of pregnancy during MS have led to clinical trials of estriol, the pregnancy estrogen, in MS. Since estriol binds to estrogen receptor (ER) beta, ER beta ligand could represent a next generation estriol treatment. Here, ER beta ligand treatment was protective in EAE in both sexes and across genetic backgrounds. Neuroprotection was shown in spinal cord, sparing myelin and axons, and in brain, sparing neurons and synapses. Longitudinal in vivo MRIs showed decreased brain atrophy in cerebral cortex gray matter and cerebellum during EAE. Investigation of ER beta ligand as a neuroprotective treatment for MS is warranted. (C) 2016 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
